Valentina Aristarco, Davide Serrano, Patrick Maisonneuve, Aliana Guerrieri-Gonzaga, Matteo Lazzeroni, Irene Feroce, Debora Macis, Elena Cavadini, Elena Albertazzi, Costantino Jemos, Emanuela Omodeo Salè, Laura Cortesi, Samuele Massarut, Marcella Gulisano, Maria Grazia Daidone, Harriet Johansson, Bernardo Bonanni
Fenretinide, a retinoid with a low toxicity profile that accumulates in the breast, has been shown to prevent second breast cancer in young women. Fenretinide exhibits apoptotic and anti-invasive properties and it improves insulin sensitivity in overweight premenopausal women with insulin resistance. The present study aimed to further characterize its role in cancer prevention by measuring circulating biomarkers related to insulin sensitivity and breast cancer risk. Sixty-two women, aged 20 to 46 years, healthy or who had already undergone breast cancer surgery, with a known BRCA1/2 mutation or a likelihood of mutation ≥ 20% according to the BRCAPRO model, were randomly assigned to receive fenretinide (200 mg/day) or placebo for 5 years (trial registration: EudraCT Number: 2009-010260-41)...
March 26, 2024: Cancer Prevention Research